ClinicalTrials.gg
RecruitingNCT07535905REVIVEUpdated Oct 22, 2026

Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients

A Phase 2 interventional study of Tamoxifen in Hypogonadism and Prostate Cancer, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know

Updated Oct 22, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike.

Tamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.

02

Conditions studied

  • Hypogonadism
  • Prostate Cancer
03

In context

Hypogonadism

320 studies on the registry are indexed under Hypogonadism; 39 are open to participants now.

This study's planned enrollment of 96 is above the median of 50 across 243 interventional studies indexed under Hypogonadism.

Browse Hypogonadism studies →

Lead sponsor

University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age;
  • Ability to understand the purposes and risks of the trial and has signed a written form. Have a diagnosis of prostate cancer;
  • Patient received ADT for a duration of either 6 or 18-36 months as part of the curative intent treatment. Curative intent prostate cancer patients who completed ADT and have had no further ADT for the length of the last ADT injection depot formulation (e.g., if the last ADT injection depot formulation is for 3 months, the patient must have no ADT for 3 months after last injection)
  • Have effectively castrated testosterone (\< 1.7 nmol/L [50 ng/dL]) within 6 weeks of enrollment;
  • Performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • Harbouring certain CYP2D6 alleles (i.e. CYP2D6*4) or from the chronic use of a CYP2D6 inhibitor(s);
  • History of blood clots (venous thromboembolism or pulmonary embolism);
  • History of stroke or (TIA);
  • Reduced liver function within last 120 days prior to enrolment, defined as follows:

    1. Total : 1.5 > (ULN) (For Gilbert's syndrome, if total bilirubin is \<1.5 x ULN, measure direct and indirect bilirubin. If direct bilirubin is greater than 1.5 x ULN, participant is ineligible;
    2. (SGOT) and ALT(SGPT): > 2.5x ULN;
    3. Or other liver disease as deemed ineligible by the investigator
  • Baseline /QTc > 500ms;
  • Active therapy with selective serotonin reuptake inhibitor (SSRI) antidepressants (e.g. paroxetine, a known CYP2D6 inhibitor);
  • Active therapy with coumarin-type anticoagulants;
  • Active therapy with cytotoxic agents;
  • Active therapy with aromatase inhibitors;
  • Other invasive within the last 5 years, other than squamous or basal cell carcinoma of the skin;
  • Treatment with a non-approved or experimental drug during the 3 months before ;
  • Patients known to have one of the following hereditary illnesses; galactose- intolerance, Lapp lactase deficiency or glucose-galactose malabsorption;
  • Any other significant concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this trial;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • No intervention
    Non-Experimental Intervention: Observation

    Participant will not receive intervention after treatment with ADT. Per routine care, participant will undergo observation for testosterone recovery

  • Experimental
    Experimental Intervention: Tamoxifen

    Participant will take 2 tamoxifen pills by mouth, every day, for a total of 40 mg each day. The duration of tamoxifen treatment will depend on the duration of the participant's previous ADT treatment. If the participant received ADT treatment for 6 months, they will receive daily Tamoxifen for 3 months. If the participant received ADT treatment for 18-36 months, they will receive daily Tamoxifen for 6 months.

    Drug: Tamoxifen

Interventions

  • Selective estrogen receptor modulator, oral tablet

06

What researchers measure

Primary outcomes

  1. Normal Testosterone Recovery

    Proportion of participants with normal testosterone levels (i.e. total testosterone \> 7.7nmol/L \[222 ng/dL\])

    Time frame: 6 months after starting intervention

Secondary outcomes

  1. Disease Control

    Measurement of PSA levels in blood

    Time frame: From enrollment to 2 years after starting treatment

  2. Patient-Reported Toxicities

    Collection and assessment of adverse events as per PRO-CTCAE version 6.0

    Time frame: From enrollment to 2 years after starting treatment

  3. Non-Castrated Testosterone Recovery

    Proportion of participants with non-castrated testosterone levels (i.e. 50-222 ng/dL\])

    Time frame: From enrollment to 2 years after starting treatment

  4. Time to Testosterone Recovery

    How long it takes for participants to reach non-castrated and normal testosterone levels

    Time frame: From enrollment to 2 years after starting treatment

  5. Urinary Function (Patient-Reported Quality of Life)

    Participant completion of the EPIC-26 questionnaire

    Time frame: From enrollment to 2 years after starting treatment

  6. Bowel Function (Patient-Reported Quality of Life)

    Participant completion of the EPIC-26 questionnaire

    Time frame: From enrollment to 2 years after starting treatment

  7. Sexual Function (Patient-Reported Quality of Life)

    Participant completion of the EPIC-26 questionnaire

    Time frame: From enrollment to 2 years after starting treatment

  8. Fatigue (Patient-Reported Quality of Life)

    Participant completion of the PROMIS-Fatigue Short Form questionnaire

    Time frame: From enrollment to 2 years after starting treatment

  9. Cognitive Function (Patient-Reported Quality of Life)

    Participant completion of the FACT-Cog questionnaire

    Time frame: From enrollment to 2 years after starting treatment

  10. Depression (Patient-Reported Quality of Life)

    Participant completion of the PROMIS Emotional Distress-Depression Short Form questionnaire

    Time frame: From enrollment to 2 years after starting treatment

  11. Overall Health (Patient-Reported Quality of Life)

    Participant completion of the EQ-5D-5L questionnaire

    Time frame: From enrollment to 2 years after starting treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Oct 2030, 46 months later.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2026
First posted
Apr 17, 2026
StartEst.
Dec 31, 2026was Jul 2026
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
University Health Network - Princess Margaret Cancer Center is now Recruiting
Oct 22, 2026
Start date
Jul 2026→Dec 31, 2026
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    University Health Network - Princess Margaret Cancer Center is now Recruiting
    Start date Jul 2026→Dec 31, 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07535905
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Oct 22, 2026

Study contacts

Alejandro Berlin, MD
Contact
alejandro.berlin@uhn.ca
416-946-4501 ext. 5813

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamoxifen

Start the discussion